# Cardiol Therapeutics Inc. (CRDL)

> Source: Nexqual · https://nexqual.com/CRDL · data as of 2026-10-15 20:00 UTC · cite as "Nexqual, Cardiol Therapeutics Inc. (CRDL), nexqual.com/CRDL" · informational, not investment advice.

**Price:** USD 1.15 (+0.88% on the day) · last close of Oct 15, 2026; US market closed, not a live price. Prev close 1.14 · day 1.13–1.17 · 52w 0.88–2.34 · market cap $140M · NCM

## Key facts
- Analysts: Buy (mean 1.67 on a 1–5 scale) (6 analysts), mean target USD 8.47 (range 4.99–11.07).
- Total return with dividends: 1Y +10.6% vs S&P 500 +18.1%; 5Y -70.7% vs S&P 500 +85.1%.
- Next earnings: 2026-11-12, EPS estimate USD -0.08, revenue estimate $0K.

## Analysts
Consensus Buy (mean 1.67 on a 1–5 scale), 6 analysts; mean target USD 8.47 (low 4.99, high 11.07).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-23 | HC Wainwright & Co. | Reiterated | Buy | $9 |
| 2026-08-17 | Canaccord Genuity | Target raised | Buy | $8 → $10 |
| 2026-07-14 | HC Wainwright & Co. | Reiterated | Buy | $9 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-16) | 5Y (from 2021-10-11) |
|---|---|---|
| Total return | +10.6% | -70.7% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | +10.6% | -21.7% |
| Volatility (annualized) | 62.6% | 79.8% |
| Max drawdown | -50.1% (Sep 2026→Oct 2026) | -89.3% (Oct 2021→Apr 2023) |

## Peers (Drug Manufacturers - Specialty & Generic)
BHC (Bausch Health Companies Inc.) USD 6.31 +7.13% · HCM (HUTCHMED (China) Limited) USD 13.94 +3.26% · LQDA (Liquidia Corporation) USD 34.78 +29.73% · AMLX (Amylyx Pharmaceuticals, Inc.) USD 27.65 +2.98% · INDV (Indivior Pharmaceuticals, Inc.) USD 33.62 -5.08% · RGC (Regencell Bioscience Holdings L) USD 9.52 +16.24%

## More
Full page: https://nexqual.com/CRDL · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt